You Are Here: U.S. Preventive Services Task Force > Topic Index > Screening: Breast Cancer > Article
Table 2. Percentage of Reduction in Breast Cancer Mortality Maintained When Moving From an Annual Screening Interval to a Biennial Interval, by Screening Strategy and Model
| Modela | Maintained Reduction in Breast Cancer Mortality, by Screening Strategy, %b | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ages 50-69 y |
Ages 40-69 y |
Ages 45-69 y |
Ages 40-79 y |
Ages 40-84 y |
Ages 55-69 y |
Ages 60-69 y |
Ages 50-74 y |
Ages 50-79 y |
Ages 50-84 y |
|
| D | 76 | 75 | 78 | 79 | 82 | 83 | 79 | 81 | 78 | 83 |
| E | 75 | 73 | 74 | 75 | 75 | 75 | 73 | 76 | 75 | 76 |
| G | 85 | 86 | 91 | 87 | 88 | 91 | 86 | 89 | 88 | 89 |
| M | 90 | 96 | 97 | 97 | 99 | 92 | 84 | 95 | 93 | 95 |
| S | 74 | 73 | 78 | 76 | 77 | 80 | 74 | 79 | 85 | 79 |
| W | 68 | 67 | 70 | 70 | 71 | 71 | 70 | 72 | 70 | 73 |
aModel group abbreviations: D = Dana-Farber Cancer Institute; E = Erasmus Medical Center; G = Georgetown University; M = M.D. Anderson Cancer Center; S = Stanford University; W = University of Wisconsin/Harvard.
b Differences in the range of results reflect differences in modeling approaches. For example, the benefit of screening in model M is modeled through stage shift, as with most other models, but also includes a "beyond stage shift" factor based on a cure fraction for small tumors. However, because many of these "cures" occur among women with invasive cancer that is not fatal, finding such cancer 1 year earlier confers very little mortality advantage to annual (vs. biennial) screening.
